Tilray/$TLRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tilray
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Ticker
$TLRY
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Leamington, Canada
Employees
2,650
ISIN
US88688T1007
Website
Tilray Metrics
BasicAdvanced
$406M
-
-$1.12
2.02
-
Price and volume
Market cap
$406M
Beta
2.02
52-week high
$2.15
52-week low
$0.35
Average daily volume
27M
Financial strength
Current ratio
2.618
Quick ratio
1.342
Long term debt to equity
11.608
Total debt to equity
12.727
Interest coverage (TTM)
-2.05%
Profitability
EBITDA (TTM)
32.028
Gross margin (TTM)
31.10%
Net profit margin (TTM)
-114.40%
Operating margin (TTM)
-11.99%
Effective tax rate (TTM)
2.47%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-1.63%
Return on equity (TTM)
-30.73%
Valuation
Price to revenue (TTM)
0.409
Price to book
0.14
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-3.871
Free cash flow yield (TTM)
-25.83%
Free cash flow per share (TTM)
-10.35%
Growth
Revenue change (TTM)
11.22%
Earnings per share change (TTM)
127.48%
3-year revenue growth (CAGR)
10.23%
10-year revenue growth (CAGR)
173.18%
3-year earnings per share growth (CAGR)
126.95%
10-year earnings per share growth (CAGR)
25.00%
What the Analysts think about Tilray
Analyst ratings (Buy, Hold, Sell) for Tilray stock.
Bulls say / Bears say
Tilray's recent acquisition of Breckenridge Distillery expands its product portfolio into the spirits market, potentially increasing revenue streams. (bloomberg.com)
The company's strategic partnership with Anheuser-Busch InBev to develop non-alcoholic cannabis beverages positions it well in the growing cannabis-infused drinks market. (reuters.com)
Tilray's expansion into the European medical cannabis market, particularly in Germany, could drive significant growth due to increasing acceptance and legalization. (seekingalpha.com)
Tilray reported a net loss of $100 million in the latest quarter, raising concerns about its path to profitability. (bloomberg.com)
The company's high debt-to-equity ratio of 1.5 indicates potential financial instability and challenges in managing its obligations. (reuters.com)
Increased competition in the cannabis market from both established companies and new entrants may pressure Tilray's market share and margins. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Tilray Financial Performance
Revenues and expenses
Tilray Earnings Performance
Company profitability
Tilray News
AllArticlesVideos
Here Is A List Of 3 Canadian Marijuana Stocks To Watch 2025
MarijuanaStocks·5 days ago
Tilray Medical Receives Italy's First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use
GlobeNewsWire·6 days ago
Elevate Your Summer with Canada's Leading Cannabis Brands and Products by Tilray Brands
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tilray stock?
Tilray (TLRY) has a market cap of $406M as of June 30, 2025.
What is the P/E ratio for Tilray stock?
The price to earnings (P/E) ratio for Tilray (TLRY) stock is 0 as of June 30, 2025.
Does Tilray stock pay dividends?
No, Tilray (TLRY) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Tilray dividend payment date?
Tilray (TLRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Tilray?
Tilray (TLRY) has a beta rating of 2.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.